Argent BioPharma Licenses Epilepsy Drug Globally and Wipes Out US$5.5M Debt
Argent BioPharma secures US$5.5 million CannEpil® global licensing deal and wipes out secured debt
Argent BioPharma (ASX: RGT) has entered a binding transaction framework for the exclusive global licensing of CannEpil®, its neurological asset for drug-resistant epilepsy, to Splash Beverage Group Inc (NYSE American: SBEV).
The deal delivers US$5.5 million in upfront consideration for the global licensing rights, satisfied through the forgiveness of US$5.5 million of Mercer Street convertible debt.
The structure produces a dual outcome for the Company. It eliminates a significant secured liability while preserving long-term participation through a 15% Net Revenue royalty, retained manufacturing rights, and 100% ownership of the underlying intellectual property.
When big ASX news breaks, our subscribers know first
How the transaction is structured
The upfront consideration is not a cash payment. Instead, the US$5.5 million is satisfied through the forgiveness of approximately US$5.5 million of Argent-issued convertible notes held by Mercer Street Global Opportunity Fund LLC (Mercer), the Company’s senior secured creditor.
The mechanism follows a three-way flow. Mercer forgives Argent’s convertible notes, and in exchange SBEV issues Mercer preferred equity with an aggregate stated value of US$5.5 million. No cash passes from Argent, and no cash is paid by SBEV to Argent.
Upon completion, the transaction fully eliminates the Company’s principal secured liability from its balance sheet and releases all associated security interests granted in connection with the Mercer facility. The Mercer facility will close with a nil balance as a result.
| Term | Detail |
|---|---|
| Upfront consideration | US$5.5M (via debt forgiveness) |
| Debt removed | ~US$5.5M secured convertible notes |
| IP ownership | 100% retained by Argent |
| Royalty to Argent | 15% of Net Revenue |
| Agreement term | 20 years + automatic 5-year renewals |
What Argent keeps — royalties, manufacturing and IP
While the exclusive worldwide licence transfers commercialisation to SBEV, Argent BioPharma retains the core economics of CannEpil®. The Company continues to participate in the product’s long-term success through a perpetual royalty arrangement while maintaining its role as manufacturing partner.
Retained value under the agreement includes:
-
100% ownership of existing and future CannEpil® intellectual property, manufacturing know-how and associated regulatory assets.
-
A 15% Net Revenue royalty on future SBEV global CannEpil® sales, including sales by its affiliates and sublicensees.
-
A royalty term payable for the longer of 10 years from first commercial sale in each country, or the expiry of the last-to-expire patent covering CannEpil® in that country.
-
Manufacturing retained through Argent’s EU-GMP facilities and EU-GMP production affiliates, priced at the Company’s fully-burdened cost of goods plus a reasonable margin of up to 20%.
This structure allows the Company to relinquish the commercialisation licence while preserving ongoing exposure to future growth through royalties and manufacturing revenues.
For investors exploring how Argent structures its licensing arrangements across different assets, our full explainer on Argent’s royalty licensing strategy covers the Aquiol five-year worldwide deal with MGC Derma, including the fixed monthly payment plus revenue-linked royalty model that mirrors the recurring revenue logic embedded in the CannEpil agreement.
Understanding CannEpil® and the drug-resistant epilepsy opportunity
CannEpil® is a pharmaceutical-grade cannabinoid combination therapy formulated as a standardised 20:1 CBD:THC oral solution, developed for the management of drug-resistant epilepsy, also referred to as refractory epilepsy.
The condition affects approximately one-third of all epilepsy patients worldwide, and the Company notes it remains one of the largest unmet needs in neurology. For investors, this represents a sizeable addressable population within the global neurology market.
CannEpil® has established regulatory and commercial credentials across multiple jurisdictions:
-
Regulatory and commercial access pathways in Ireland, the United Kingdom, Germany and Australia.
-
Full reimbursement status in Ireland under the Medicinal Cannabis Access Programme.
-
Completion of the largest commercial shipment in the product’s history, with 1,000 units delivered into the Irish market.
The CannEpil Ireland shipment earlier this year, comprising 1,000 units valued at approximately A$783,000 and fully reimbursed under the national Medicinal Cannabis Access Programme, established the commercial proof-of-concept that underpins the licensing value now being transferred to SBEV.
- An active FDA IND programme in the United States, supported by real-world clinical evidence and peer-reviewed publications.
Development milestones SBEV must deliver
The agreement establishes a milestone-driven pathway rather than a passive sale, with SBEV responsible for development and regulatory approval. Under the terms, SBEV must use commercially reasonable efforts to:
-
Initiate a Phase I clinical trial within 24 months.
-
Initiate a Phase II clinical trial within 48 months.
-
File an FDA New Drug Application (NDA) following successful clinical trials.
-
Launch CannEpil® within 12 months of regulatory approval in any country, and maintain an active commercial presence.
The United States is to be prioritised for development and regulatory approval. Splash Beverage Group is a NYSE American-listed company headquartered in Fort Lauderdale, Florida, pursuing a strategic transformation toward becoming a cannabinoid health, wellness and biopharmaceutical platform.
Chairman’s perspective
Roby Zomer, Chairman
“The CannEpil® licensing transaction represents one of the most significant milestones achieved by Argent BioPharma to date.
The transaction delivers US$5.5 million of upfront consideration for CannEpil® and will remove approximately US$5.5 million of secured debt from the Company’s balance sheet. Importantly, Argent retains ownership of the underlying intellectual property, manufacturing capabilities, and a perpetual participation in future revenues through royalties.
We believe this structure achieves a highly attractive outcome for shareholders by simultaneously strengthening the Company’s financial position, simplifying its capital structure, and creating a pathway for the global commercialisation of CannEpil®. Importantly, the agreement requires SBEV to file a New Drug Application (NDA) with the FDA in the event of successful clinical trials.
As we continue to advance our broader neuro-immune portfolio and U.S. growth strategy, this transaction positions Argent BioPharma with a stronger balance sheet, a clearer strategic focus, and ongoing participation in the long-term value creation potential of CannEpil®.”
The next major ASX story will hit our subscribers first
Why the deal matters for shareholders and what comes next
The transaction strengthens the balance sheet and removes what the Company describes as a long-standing financing overhang. Argent believes it also supports progression toward a U.S. national exchange listing transaction.
By eliminating the secured debt, the Company gains increased strategic flexibility to advance its broader neuro-immune portfolio and U.S. growth strategy, led by CannEpil® and CimetrA®.
The agreement remains subject to satisfaction or waiver of certain conditions precedent. These include completion of the debt exchange with Mercer, receipt of all necessary board and shareholder approvals from both Argent and SBEV, and no material adverse effect having occurred in respect of either party. The licence will only become effective once these conditions are satisfied or waived.
The Company believes the transaction unlocks immediate value from one of its most advanced assets while preserving meaningful long-term economic exposure to future commercial success through royalties, manufacturing revenues, and continued ownership of the underlying intellectual property.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already getting the edge on market-moving announcements. Click the “Free Alerts” button at StockWire X to make sure the next major deal lands in your inbox before the market moves.